Evidence map›Paper›PMID 36741943›Full record

ArticleJournal of the Endocrine Society2023

Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.

Mara Kinney, Lu You, Emily K Sims, Diane Wherrett, Desmond Schatz, Sandra Lord, Jeffrey Krischer, William E Russell, Peter A Gottlieb, Ingrid Libman and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Mara KinneyBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-3806-9295
Lu YouHealth Informatics Institute, University of South Florida, Tampa, FL 33620, USA.
Emily K SimsDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Diane WherrettDepartment of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto M5G 1X8, Canada.
Desmond SchatzDepartment of Pediatrics, University of Florida, Gainesville, FL 32611, USA.
Sandra LordDiabetes Research Program, Benaroya Research Institute, Seattle, WA 98101, USA.
Jeffrey KrischerHealth Informatics Institute, University of South Florida, Tampa, FL 33620, USA.
William E RussellVanderbilt University Medical Center, Nashville, TN 37232, USA.
Peter A GottliebBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Ingrid LibmanDivision of Endocrinology, Diabetes and Metabolism, University of Pittsburgh and UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15213, USA.
Jane BucknerDiabetes Research Program, Benaroya Research Institute, Seattle, WA 98101, USA.ORCID https://orcid.org/0000-0002-9005-1885
Linda A DiMeglioDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Kevan C HeroldDepartments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Andrea K SteckBarbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA.ORCID https://orcid.org/0000-0002-5931-9484
University of Colorado Denver · USBenaroya Research InstituteIndiana University School of MedicineUniversity of South Florida · USUniversity of Florida · USUniversity of Pittsburgh · USUniversity of Toronto · CAVanderbilt University Medical Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Implications of Changes in Islet Exosomal Cargo in Type 1 DiabetesR01DK133881 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA, MIRMIRA, RAGHAVENDRA G · 2022 to 2025
$2.7M
Beta cell extracellular vesicles in health and diseaseR01DK121929 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI SIMS, EMILY K · 2020 to 2024
$2.0M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK121929NIDDK NIH HHS R01 DK133881
6 · The paper itself

Abstract

Context: Participants with stage 1 or 2 type 1 diabetes (T1D) qualify for prevention trials, but factors involved in screening for such trials are largely unknown. Objective: To identify factors associated with screening for T1D prevention trials. Methods: This study included TrialNet Pathway to Prevention participants who were eligible for a prevention trial: oral insulin (TN-07, TN-20), teplizumab (TN-10), abatacept (TN-18), and oral hydroxychloroquine (TN-22). Univariate and multivariate logistic regression models were used to examine participant, site, and study factors at the time of prevention trial accrual. Results: Screening rates for trials were: 50% for TN-07 (584 screened/1172 eligible), 9% for TN-10 (106/1249), 24% for TN-18 (313/1285), 17% for TN-20 (113/667), and 28% for TN-22 (371/1336). Younger age and male sex were associated with higher screening rates for prevention trials overall and for oral therapies. Participants with an offspring with T1D showed lower rates of screening for all trials and oral drug trials compared with participants with other first-degree relatives as probands. Site factors, including larger monitoring volume and US site vs international site, were associated with higher prevention trial screening rates. Conclusions: Clear differences exist between participants who screen for prevention trials and those who do not screen and between the research sites involved in prevention trial screening. Participant age, sex, and relationship to proband are significantly associated with prevention trial screening in addition to key site factors. Identifying these factors can facilitate strategic recruitment planning to support rapid and successful enrollment into prevention trials.

Indexed as

drug clinical trialsenrollmentpreventionrecruitmenttype 1 diabetes

Identifiers

PMID36741943
PMCPMC9891344
OpenAlexW4315471319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.